Advancements in Urothelial Cancer Care: Optimizing Treatment for Your Patient.
Am Soc Clin Oncol Educ Book
; 44(3): e432054, 2024 Jun.
Article
de En
| MEDLINE
| ID: mdl-38771987
ABSTRACT
The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing to personalize treatment by incorporating biomarkers to better guide treatment selection. In addition, bladder preservation strategies are aimed at avoiding cystectomy in well-selected patients. Similarly, in the metastatic urothelial cancer space, the standard frontline treatment option of platinum-based chemotherapy has changed with the availability of data from EV-302 trial, making the combination of enfortumab vedotin (EV) and pembrolizumab the preferred first-line treatment option. Here, we examine the optimization of treatment intensity and sequencing, focusing on the challenges and opportunities associated with EV/pembrolizumab therapy, including managing toxicities and exploring alternative dosing approaches. Together, these articles provide a comprehensive overview of contemporary strategies in bladder cancer management, highlighting the importance of individualized treatment approaches, ongoing research, and multidisciplinary collaboration to improve patient outcomes in this complex disease landscape.
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs de la vessie urinaire
Limites:
Humans
Langue:
En
Journal:
Am Soc Clin Oncol Educ Book
/
American Society of Clinical Oncology educational book
Année:
2024
Type de document:
Article
Pays de publication:
États-Unis d'Amérique